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The concept of liver transplantation is a rela-
tively recent one. The first descriptions of liver re-
placement in experimental animals were published 
less than 25 years ago,I,2 and the first attempt at 
clinical liver transplantation was not made until 
March I, 1963.3 The pace of clinical trials remained 
limited until 1980, the year when the new immuno-
suppressive agent cyclosporine was introduced. In 
the following article, the way in which immunosup-
press: on was developed before and after 1980 will 
be described, as well as the influence of other non-
operative factors that conspired to make liver trans-
plantation practical. Surgical technical advances will 
be considered elsewhere in this issue of Seminars. 
IMMUNOSUPPRESSION 
Truly long survival after liver transplantation 
between outbred mongrel dogs was demonstrated 
more than 20 years ago in ten dogs under treatment 
with azathioprine who lived for 4 postoperative 
months.4 After this time, their drug therapy was 
discontinued. A number of these animals lived for 
long periods,5 and one did not die until more than 
10 years later. A short time later, similar results 
were obtained with heterologous antilymphocyte 
serum (ALS) and its globulin derivative (ALG).6 
The number of animals that survived chroni-
cally in these investigations was less than 10070 of 
the total. Nevertheless, proof of the feasibility of 
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liver replacment· under these difficult laboratory 
conditions was the great stimulus for the first clini-
cal trials. The first human liver recipient to survive 
for at least 1 year was operated on in the summer of 
1967,7 and ·the longest survival of a patient is now 
15 Yz years. This recipient, whose original disease 
was biliary atresia with an incidental hepatoma, was 
treated with azathioprine, and ALG. 
IMMUNOSUPPRESSION BEFORE 
CYCLOSPORINE 
Renal Transplantation 
All of the immunosuppressive regimens that 
have made whole liver transplimtation feasible were 
worked out with the simpler model of renal trans-
plantation (Table 1), beginning in Boston in 1962 
with the use of azathioprine as the sole or principal 
immunosuppressive agent. 8 There were no long 
survivors, and since that time, it has been recog-
nized that cadaver organ transplantation could 
rarely, if ever, be successful using azathioprine 
alone. 
In 1962 and 1963, it was demonstrated in renal 
transplant recipients that azathioprine and steroids 
had at least additive, if not synergistic, actions.9 
This so-called double-drug therapy was adopted in 
three other centers 10-12 and became the gold 
standard worldwide by 1964. However, satisfactory 
results then13 and for more than a decade were ob-
tained only with living related donors. The 
morbidity and mortality from the transplantation of 
cadaveric kidneys were excessive and the rate of 
graft function at 1 year hovered at the 50% range 
for many years. 14 
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TABLE 1. Immunosuppressive Drug Regimens and Adjuncts Initially Developed for 
Kidney Transplantation and Applied Later for Extrarenal Organs 
Year 
Described Used for 
Agents or Reported Place Deficiencies Livers 
Azathioprine 19628 Boston Ineffective, dangerous No 
Azathioprine-steroids 1963 9 Denver Suboptimal Yes 
Thoracic duct drainage as adjunct 1963 21 * Stockholm Nuisance: requires 20 to 30 days Yes 
pretreatment 
ALG as adjunct 19666 Denver Suboptimal Yes 
Cyclophosphamide substitute for 197020 Denver No advantage except for patients Yes 
azathioprine with azathioprine toxicity 
Total lymphoid irradiation 1979 23 Palo Alto, Dangerous; extensive preparation; Yes 
1984 24 Minneapolis not quickly reversible 
Cyc1osporine alone 1978-197927 Cambridge Suboptimal Yes 
Cyc1osporine-steroids 198029 Denver Under evaluation Yes 
Monoclonal ALG as adjunct 1981 17 Boston Under evaluation Yes 
*It was not realized until much later that pretreatment for 3 to 4 weeks before transplantation was a necessary condition.22 
Although the addition of ALG as a third and 
short-term immunosuppressive adjunct6,15 im-
proved the results of renal transplantation in most 
centers in which this expedient was tried, the use-
fulness of ALG was limited. The drug could not 
be standardized, it had a number of undesirable 
side effects, and its discontinuance often was fol-
lowed by rejection.5,15 
There has been a resurgence of interest in ALG 
therapy, since it is now possible to raise potent and 
highly standardized antilymphoid antibodies with 
the monoclonal antibody techniques of Kohler and 
Milstein.16 The first trials with this improved pro-
duct were carried out by Cosimi et al17 about 5 
years ago using monoclonal antibodies raised 
against mature T-lymphocytes (T3). These studies 
and others that have followed have shown that 
otherwise intractable rejections of renal homografts 
often can be reversed with good monoclonal prep-
arations. 18,19 However, if maintenance therapy is 
being provided with azathioprine and prednisone, 
there is a very high probability of recurrence of re-
jection when the course of monoclonal therapy is 
completed.17-19 
Other variations in immunosuppression be-
tween 1962 and 1979 are summarized in Table 1, 
including the substitution of cyclophosphamide for 
azathioprine,20 and the use of thoracic duct drain-
age21 ,22 or total lymphoid irradiation23,24 as an 
alternative to ALG for lymphoid depletion. None 
of these techniques has had a major impact on clini-
cal transplantation. 
Liver Transplantation 
Most of our liver recipients from 1963 through 
1979 had triple-drug immunosuppression with aza-
thioprine, prednisone, and ALG. In some, cyclo-
phosphamide was substituted for azathioprine, and 
in a few others, lymphoid depletion was achieved 
with thoracic duct drainage instead of ALG. Details 
of these variations are summarized elsewhere.25 
None of the variations influenced survival after 
liver transplantation (Fig. 1). In the first trials from 
1963 to 1976, only about one third of the patients 
lived for as long as 1 year. In a smaller second 
series of 30 patients treated form 1976 to 1978, the 
I-year survival rose to 50070, but this improvement 
could not be sustained in the next 29 cases (Fig. 1). 
IMMUNOSUPPRESSION WITH 
CYCLOSPORINE 
In 1976, Borel et al26 reported studies in 
rodents of a new immunosuppressive agent called 
cyclosporin A. In late 1979, CaIne and his associ-
ates27 reported the first major clinical experience 
with this drug. 
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FIG. 1. Results obtained over a 16-year period using the 
conventional immunosuppression regimens without cyclo-
sporine, as shown in Table 1. Note the failure to improve the 
results despite the acquisition of considerable technical experi-
ence. 
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Renal Transplantation 
CaIne et al 27 noted that cyclosporin A had pro-
longed graft survival in almost half of the recipients 
of 32 kidneys, two livers, and two pancreases with 
no other immunosuppressive drug, an unprece-
dented achievement with a single agent. The publi-
cation was one of the most important in the history 
of clinical transplantation. Nevertheless, it con-
tained three pieces of information so troubling that 
further clinical trials were jeopardized. First, three 
of the first 34 recipients had developed malignant 
lymphomas. Second, none of the kidney recipients 
had normal graft function. Third, there had been a 
high patient mortality. These adverse findings have 
been explained or minimized in subsequent trials. 
Development of lymphomas 
The incidence of lymphomas in CaIne and as-
sociates,27 first 32 kidney recipients raised the possi-
bility that cyclosporin A had a unique capacity to 
produce lymphomas in humans, thus vitiating its 
value. Fortunately, the lymphoma threat became 
less and less ominous as information about the 
etiology and appropriate treatment of these lesions 
emerged. It became obvious that the lymphomas 
Wf'fe caused by primary or secondary infection with 
the Epstein-Barr virus.28 ,29 Although it was specu-
lated that lymphomas that produced a single immu-
noglobulin (monoclonality) already had become 
autonomous,28 this doctrine was overthrown.30 In a 
large number of patients followed by us, it was 
demonstrated that all of the cyclosporine lympho-
mas that developed early postoperatively could be 
expected to disappear spontaneously if immunosup-
pressive therapy was stopped, and often if treat-
ment was only lightened. The regression occurred 
whether the lesions were polyclonal or monoclonal. 
In recipients of' kidneys, livers, and hearts, reduc-
tion or discontinuance of immunosuppression was 
not necessarily followed by loss of the transplanted 
organ. Of seven of our kidney recipients in whom 
therapy with cyclosporine and steroids was stopped 
or drastically reduced, four retained their grafts, 
which have continued to function for 1112 to 3 Y2 
years subsequently. After the tumors had disap-
peared, immunosuppressive therapy at lower doses 
was reinstituted. Similar involution of lymphomas 
has been seen in several liver recipients. 
The development of de novo malignancies in 
immunosuppressed p,atients is not unique to cyclo-
sporine. It has been a well-known complication of 
therapy with azathioprine and prednisone (with or 
without ALG) since the 1960s.31 ,32 With conven-
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tional immunosuppression, there has been an 
extremely high incidence of epithelial cancers, which 
have outnumbered the lymphomas by 'a ratio of 
about 4 to 1.33 Under cyclosporine-steroid therapy, 
there has been little or no increase in the incidence 
of the epithelial tumors. Thus, the risk of the devel-
opment of malignancies is f)robably considerably 
less with cyclosporine than with conventional immu-
nosuppression, even if one considers the lymphomas 
to be true tumors, a concession that may not be 
valid.34 
Cyclosporine Nephrotoxicity 
and Its Prevention 
Of the kidney recipients first reported by Caine 
et al,27 none had normal renal function, a finding 
that they attributed to universal cyclosporin A 
nephrotoxicity. In retrospect, part of the problem 
was failure to distinguish rejection from drug 
toxicity.29 Nevertheless, many subsequent reports, 
including our own,29,35,36 have shown that nephro-
toxicity is the most limiting side effect of cyclo-
sporine. 
The full exploitation of the drug was not possi-
ble without combining it with other agents, of 
which prednisone was the most important.29,36 By 
this polypharmacy approach, it was possible to 
control rejection better even though smaller and less 
nephrotoxic doses of cyclosporine were used. Since 
then, other drugs have been proposed or tried in 
modifications of the "pharmacologic cocktail" con-
cept,37,38 but cyclosporine and steroids constitute 
the basic combination, to which other agents can be 
added, For example, cyclosporine and steroids can 
provide the baseline therapy to which one of the 
monoclonal ALG preparations that are undergoing 
preliminary clinical trials may be added. Our 
present opinion is that monoclonal ALG should be 
used to "rescue" patients in whom rejection cannot 
be controlled with cyclosporine-steroid therapy or in 
whom there are severe limitations for one reason or 
another to the amounts of cyclosporine that can be 
safely given. Such limitations are particularly im-
portant in applying knowledge about immunosup-
pression obtained from the kidney transplant model 
to the transplantation of other organs, such as the 
heart and liver, since secondary renal failure is 
common in patients with cardiac and hepatic dis-
ease, thereby complicating the use of cyclosporine. 
OKT3 monoclonal antibody therapy has been 
used in a number of our kidney recipients. If rejec-
tion has developed despite cyclosporine-steroid 
therapy, reversal with OKT3 antibody usually has 
been striking (Fig. 2). With the first dose of the 
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FIG. 2. Course of a recipient of a kidney graft who devel-
oped inexorable renal rejection despite good blood levels 
of cyclosporine and despite a second burst of high-dose 
steroid therapy, The rejection was immediately reversed with 
OKT3 therapy and with good function for the ensuing 8 months. 
Note the prompt reduction in circulating T-Iymphocytes_ 
monoclonal ALG, the circulating T -lymphocytes are 
practically eliminated (Fig. 2). Recurrence of rejec-
tion after the monoclonal antibody course has been 
completed has been far less common using baseline 
therapy with cyclosporine-steroids than previously 
reported with azathioprine-prednisone mainte-
nance. 17-19 
High Patient Mortality 
The heavy mortality with the first use of cyclo-
sporine27 apparently was a reflection of a learning 
experience in which cytotoxic drugs and steroids 
often were combined with cyclosporine with lethal 
effects. Even in our first trials with the far safer 
cyclosporine-steroid combination, the I-year patient 
mortality following renal transplantation was 
13.6070,39 but in the following year, the I-year 
mortality was reduced to 2%.40 Since then, most 
groups using cyclosporine-steroid therapy have had 
a mortality of less than 5%. Cyclosporine-steroid 
therapy has been the safest of the therapeutic regi-
mens yet tried. 
Liver Transplantation 
In 1980, cyclosporine and prednisone were used 
to treat 12 patients undergoing liver replacement. 
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Two other liver recipients died on the operating 
table for a total patient pool in that year of 14, of 
whom 11 (78%) lived out the first year. If one 
counted only those who actually survived the opera-
tion to be able to receive drug therapy, the success 
rate was 11 of 12. (91.7%). These improved results 
became known in 1981,41 and almost immediately a 
remarkable effect was seen on the case numbers. 
Increments occurred year-by-year until in 1984 a 
total of 166 orthotopic liver transplantations were 
performed at the University of Pittsburgh (Fig. 3). 
Increased activity in other centers throughout the 
world has been documented elsewhere.42 
Our early trials of cyclosporine-steroid therapy 
were conducted without knowing what the cyclo-
sporine blood levels were. The clinical judgment in 
managing such patients reflected a deliberate effort 
to balance the possibilities of rejection against those 
of nephrotoxicity.36 
When techniques became available for assess-
ment of whole blood or plasma cyclosporine con-
centration using radioimmunoassay (RIA) or high-
performance liquid chromatography (HPLC), as 
described elsewhere in this issue of Seminars, it 
became popular to rely heavily on the results of 
these tests for management decisions. Recipients of 
liver transplantation have benefited from this 
practice, since intestinal absorption of cycIosporine 
after liver transplantation is unpredictable, as dis-
cussed elsewhere in this issue of Seminars. To 
assure adequate cycIosporine blood concentrations, 
it frequently has been necessary to administer the 
drug both intravenously and by mouth for several 
days, weeks, or even months postoperatively (Fig. 
4). As absorption improves with the oral route, the 
intravenous doses are slowly reduced. Nevertheless, 
blind faith in the cyclosporine blood levels cannot 
be used to replace good clinical judgment, since 
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FIG. 3. Increasing numbers of liver transplantations at the 
University of Pittsburgh between 1981 and 1984. Note the 
significant number of retransplantations. 
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FIG. 4. The use of cyclosporlne and steroids. Note that the cyclosporine initially is given 
intravenously (IV) and that the IV therapy is continued long after the drug is begun orally. The 
switch from double-route cyclosporine therapy to the oral route alone is carefully monitored 
with cyclosporiRe blood levels. Note the seeming increase in enteral absorption after clamping 
of the T-tube, the insistence on maintaining high blood levels of cyclosporine despite obvious 
low-grade nephrotoxocity, and the intensification of steroid therapy with either a cycle or 
intermittent bolus administration with suspicion of rejection. Large arrows: methylprednisolone 
sodium succinate; small arrows: hydrocortisone sodium succinate. (Reproduced with permission 
from Starzl et al.42 ) 
toxicity of the drug - including that affecting the 
liver as well as the kidney - does not have an abso-
lute correlation with the blood level. 
NON RELEVANCE OF TISSUE TYPING 
Antigen matching at the A, B, or DR loci has 
had little influence on the results after cadaveric 
renal transplantation and has not even been at-
tempted for liver recipients. This kind of tissue 
matching probably will not playa significant role in 
further developments in liver transplantation. 
A surprising finding has been the remarkable 
resistance of .the liver to hyperacute rejection.43 •44 
There has been no obvious penalty with transplan-
tation of livers to recipients whose sera contain the 
cytotoxic antigraft antibodies that almost invariably 
lead to immediate loss of kidney grafts. Further-
more, many liver transplantations have been and 
are being carried out across the ABO blood group 
barriers that frequently (although not invariably) 
cause hyperacute rejection of kidneys as the con-
sequence of antigraft isoagglutinins.13 These obser-
vations have simplified enormously the logistic 
problems of liver transplantation. 
CURRENT INDICATIONS FOR 
TRANSPLANTATION 
The indications for liver replacement in the 
developmental phase of this field have been docu-
mented elsewhere25 and will not be mentioned here. 
Subsequent to the beginning of the cyclosporine 
era, 244 patients underwent this procedure between 
March 1980 and July 1, 1984. In Tables 2 and 3 are 
shown the principal indications for these operations. 
In about 100/0 of cases there were multiple patho-
logic diagnoses, such as the incidental presence of 
primary hepatic malignancies in livers with a variety 
of underlying chronic diseases. 
The profile of diseases in pediatric patients 
(less than 18 years old) has been different from that 
in adults. In adults, postnecrotic cirrhosis has been 
the most important reason for proceeding (Table 2). 
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TABLE 2. Indications for Liver Transplantation 
in 140 Adults, 3/1/80 - 7/1/84 
Indication Number Percent 
Acute hepatic necrosis 3 2.1 
Budd-Chiari syndrome 5 3.6 
Cirrhosis 46 32.9 
Inborn errors of metabolism 11 7.9 
Alpha I-antitrypsin deficiency 6 4.3 
Wilson's disease 3 2.1 
Tyrosinemia 0.7 
Primary biliary cirrhosis 36 25.7 
Primary hepatic tumors 13 9.3 
Secondary biliary cirrhosis 5 3.6 
Sclerosing cholangitis 19 13.6 
Other 2 1.4 
TABLE 3. Indications for Liver Transplantation 
in 104 Children, 3/1/80 - 7/1/84 
Indication Number Percent 
Biliary atresia 56 53.8 
Budd-Chiari syndrome 1.0 
Cirrhosis 10 9.6 
Familial cholestasis 7 6.7 
Inborn errors of metabolism 23 22.1 
Alpha I-antitrypsin deficiency 15 14.4 
Wilson's disease 4 3.8 
Tyrosinemia 3 2.9 
Neonatal hepatitis 3 2.9 
Secondary biliary cirrhosis 1.0 
Sclerosing cholangitis 1.0 
Other 2 1.6 
Other common diseases in adults have been primary 
biliary cirrhosis and sclerosing cholangitis (Table 2). 
In children, more than half of all the transplanta-
tions have been done for biliary atresia, the only 
other large group being a heterogenous collection of 
inborn errors of metabolism (Table 3). The inborn 
errors, if they are hepatic-based, are cured perma-
nently by liver replacement, since the phenotype of 
the new liver remains that of the original donor.5,25 
FACTORS INFLUENCING SURVIVAL 
Cyclosporine 
From 1963 through 1979, 170 patients were 
treated with conventional immunosuppression. The 
chances of living for a year after liver transplanta-
tion were only about one in three (Fig. 5). Subse-
quently, 244 liver recipients were provided with 
cyclosporine-steroid therapy between March 1980 
and July 1, 1984, allowing follow-ups of 1 to more 
than 5 years. The chances of I-year survival were 
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FIG. 5. Marked improvement in results of liver transplanta-
tion after the introduction of cyclosporine-steroid therapy 
in ealry 1980. 
more than doubled. Actuarial projections beyond I 
year indicate that these gains will be sustained for at 
least half a decade (Fig. 5). The results that fol-
lowed the introduction of cyclosporine (Fig. 5) are 
appreciably greater than in the years that preceded 
its use (Fig. 1), indicating that cyc1osporine per se 
was a major factor in achieving the improved results. 
Age 
Aside from the fact that the disease profiles 
leading to transplantation are different in children 
and adults, another justification for stratification 
into adult and pediatric categories is the influence 
of age on survival. It was noted in the days of con-
ventional immunosuppression that the results were 
better in pediatric recipients (Fig. 6). The disparity 
in pediatric versus adult cases has been even more 
striking during the cyclosporine era (Fig. 7). The 
actuarial 5-year survival in adults is projected at 
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FIG. 6. Results with adult versus pediatric liver transplan-
tation under conventional immunosuppression between 
1963 and early 1980. 
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FIG. 8. Percentages of liver transplantations in pediatric 
versus adult recipients at the University of Pittsburgh from 
1981 through most of 1984. 
about 50070, compared with more than 70% for the 
pediatric recipients (Fig. 7). In view of the impor-
tance of the age factor, it will be necessary for 
groups reporting results to stipulate age distribution 
in their series. In our own experience using conven-
tional immunosuppression from 1963 to 1979, half 
of the recipients were infants, children, and teen-
agers. In the subsequent years using cyclosporine, 
the pediatric component has never been that high 
(Fig. 8). 
With the appropriate age stratification, mean-
ingful comparisons become possible between what 
was achievable in the precyclosporine era versus 
now. In adults, the projected 5-year survival after 
liver transplantation, while still unsatisfactory, is 
nearly three times better than it was previously (Fig. 
9). In children, the divergence of results using con-
ventional immunosuppression compared with the 
present time is even more striking (Fig. 10). 
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FIG. 9. Survival of adult liver recipients in the precyclo-
sporine versus the cyclosporine eras. 
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FIG. 10. Survival of pediatric patients in the precyclo-
sporine versus the cyclosporlne eras. Notice the remarkably 
high survival of children treated with cyclosporine-steroids during 
the first postoperative year as well as the fact that subsequent 
losses were extremely uncommon. 
Influence of Diseases on Prognosis 
There are no diseases for which transplantation 
has been carried out in the past that can be auto-
matically precluded from future trials. Usually, the 
nature of the original disease has not profoundly 
influenced the outcome after transplantation. For 
example, the results in adults have been similar with 
such diverse diseases as primary biliary cirrhosis, 
sclerosing cholangitis, and inborn errors of metabo-
lism (Fig. 11). Nevertheless, there may be some 
high-risk diseases. So far, the results with post-
necrotic cirrhosis and with primary hepatic tumors 
have been inferior (Fig. 12). With cirrhosis, the 
principal explanations have been the technical dif-
ficulties of the operation caused by the pathologic 
process, the generally poor condition of the pa-
tients, and almost universal recapitulation of their 
original chronic active hepatitis in B virus carriers. 
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FIG. 11. The lack of influence of the underlying disease in 
adults treated for primary biliary cirrhosis. sclerosing cho-
langitis. and inborn errors of metabolism. 
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FIG. 12. Life survival curves of patients with cirrhosis and 
primary hepatic malignancy. Note the very high survival of 
patients with malignant disease during the first half year (856 ). 
but with a steady decline thereafter, which was due primarily to 
the development of metastases. 
In patients whose reason for liver replacement 
was a primary hepatic malignancy that could not be 
removed by conventional subtotal hepatic resection, 
the early mortality has been quite low, with more 
than 800/0 of the recipients being alive at 6 months. 
The steady decline thereafter (Fig. 12) has been 
caused by recurrent tumor, which can be expected 
in 80% or more of patients who live long enough 
for metastases to be detected. The only acceptable 
results thus far have been in patients with the slow-
growing and nonaggressive fibrolamellar hepato-
mas, which recently have been recognized to be a 
favorable variant within the larger hepatoma cate-
gory.45 No patient has ever been cured of a duct cell 
carcinoma by liver transplantation. This has been 
unexpected, since the small duct cell carcinomas at 
the confluence of the right and left hepatic ducts 
(Klatskin tumors) were once thought to be an al-
most ideal indication for liver replacement. 
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In children, the results have been about the 
same in all of the main disease categories (Fig. 13). 
It was thought once that the technical problems in 
frequently reoperated children with biliary atresia 
would result in an increased mortality. Almost all 
such infants and children have had portoentero-
stomies and many have had multiple later surgical 
interventions in and around the hepatic hilum. Al-
though transplantation is technically much more 
difficult under such circumstances, there has been 
no demonstrable penalty in terms either of early or 
late survival (Fig. 13). 
ROLE OF RETRANSPLANTATION 
Before the cyclosporine era, retransplantation 
in the event of failure of the first liver was almost 
never successfu1.25 The effectiveness of retransplan-
tation has improved greatly since t'he introduction 
of cyclosporine, with an expected I-year survival of 
almost 50%, as documented elsewhere in this issue 
of Seminars. The success rate for patients whose 
grafts have been in place for some time and failed 
slowly because of rejection has been especially high. 
The worst results have been in patients with imme-
diate and serious technical complications and those 
whose grafts have undergone a rapid and uncon-
trolled rejection in the first week or two. 
The role of retransplantation in the future has 
been somewhat clouded by the enormous economic 
ramifications of early technical or other complica-
tions serious enough to warrant replacement of the 
graft. In his article in this issue of Seminars, Luebs 
has provided data about these fiscal implications at 
the Children's Hospital of Pittsburgh. 
Both in adults and in children, but particularly 
the latter, technical complications have played an 
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FIG. 13. Lack of influence of underlying disease on the sur-
vival of children undergoing liver transplantation. 
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important role in necessitating attempts at retrans-
plantation.46 The lesson has been clear that if a per-
fect operation is not performed the first time for 
any reason, the cost will be prodigous and will have 
to be borne by the patient or more commonly the 
health insurance carrier. In future years, it will 
become important t9 try to identify those patients 
for whom retransplantation offers little or no 
chance of survival so that expensive an~ ineffective 
attempts can be avoided with some degree of ac-
curacy. 
DIAGNOSIS OF POSTOPERATIVE 
LIVER DYSFUNCTION 
In the early days of liver transplantation, the 
development of hepatic dysfunction postoperatively 
was quite naturally attributed to rejection. This 
diagnosis was usually correct, but not always. Fre-
quent alternative explanations were complications 
of biliary tract reconstruction; infection with 
hepatitis B virus, cytomegalovirus, herpes, or ade-
novirus; and drug toxicity. The ability accurately 
to differentiate these causes from rejection has 
resulted from the great advances in hepatology, in-
fectious disease, radiology, and pathology of the 
last two decades. With the combination of a hepa-
titis antigen/antibody screen, noninvasive radiologic 
imaging techniques, cholangiography, angiography 
on occasion, and needle biopsy of the liver, treat-
ment can be tailored for each individual patient in a 
far more effective way. 
SUMMARY 
During the last 5 years, liver transplantation 
has become a service as opposed to an experimental 
operation. The most important factor in making 
this possible has been the introduction of cyclo-
sporine-steroid therapy. At the same time, liver 
transplantation has been made more practical by 
improvements in diagnosing and managing other 
causes of postoperative hepatic dysfunction. Tissue 
typing and matching have played no role in improv-
ing the results of liver transplantation. With the 
demonstration that preformed antibody states are 
irrelevant, even avoidance of positive cross-matches 
caused by cytotoxic antibodies and observance of 
ABO blood group barriers have become unneces-
sary if the recipi~ntDs needs are great. With the 
exceptions of malignancy and cirrhosis, the nature 
of the underlying hepatic disease has not profound-
ly influenced the results. Retransplantation has 
SEMINARS IN LIVER DISEASE- VOL. 5, NO.4, 1985 
played an important role in improving survival, al-
though the costs of retransplantation have been 
extremely high. 
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